Management of Refractory Hypomagnesemia

Introduction to Hypomagnesemia Management

The American Gastroenterological Association recommends immediately discontinuing pantoprazole and switching to an H2-blocker (ranitidine or famotidine), as PPIs are a well-established cause of severe, treatment-resistant hypomagnesemia that resolves within 2 weeks of cessation 1.

If acid suppression is absolutely necessary, switch to an H2-blocker (ranitidine or famotidine), which does not impair magnesium absorption, according to the European Society of Gastrointestinal Endoscopy 1.
Before any magnesium supplementation, aggressively rehydrate with intravenous normal saline to correct sodium and water depletion, as secondary hyperaldosteronism from volume depletion causes massive renal magnesium and potassium wasting that overrides any supplementation effort, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 2.

Measure 24-hour urine magnesium and calculate Fractional Excretion of Magnesium (FeMg%) to distinguish renal from gastrointestinal losses, recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) foundation 3.
Check serum creatinine and eGFR before any magnesium supplementation—avoid magnesium if creatinine >2.5 mg/dL or eGFR <30 mL/min/1.73m² due to life-threatening hypermagnesemia risk, as advised by the European Renal Association 6.

For mild-moderate impaired renal function (eGFR 30-60 mL/min), use oral magnesium oxide 12-24 mmol daily (480-960 mg elemental magnesium), divided into doses and given at night when intestinal transit is slowest, as suggested by the American College of Gastroenterology 2.
Organic magnesium salts (magnesium citrate, aspartate, lactate) have superior bioavailability compared to magnesium oxide or hydroxide and should be preferred, according to the National Institutes of Health 1.

Hypomagnesemia causes dysfunction of multiple potassium transport systems and increases renal potassium excretion—hypokalemia will remain refractory to potassium supplementation until magnesium is normalized, as stated by the American Heart Association 2.
Do not attempt aggressive potassium replacement until magnesium is corrected, as it will be ineffective and waste resources, advised by the European Society of Cardiology 2.

Recheck serum magnesium, potassium, calcium, and renal function 48-72 hours after initiating treatment, recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) foundation 3.
Target plasma magnesium >0.6 mmol/L (>1.5 mg/dL), as suggested by the American College of Cardiology 1.
Continue monitoring weekly until stable, then monthly, advised by the European Renal Association 1.